Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated the antioxidant capacities of essential oils from myrtle and orange commonly used in the Adana region and found that myrtle essential oil exhibited a higher antioxidant activity than orange essential oil when tested with the DPPH assay.

In this study, extracts of Zataria multiflora Boiss. and Matricaria chamomilla, combined with minoxidil, significantly improved hair growth in androgenetic alopecia patients by potentially inhibiting 5α-reductase activity.

This study found that using a stevioside-based microneedle patch significantly increased minoxidil's solubility and skin absorption, promoting hair growth in animal models and achieving 67.5% area coverage by day 35, highlighting the potential of this novel delivery system for androgenetic alopecia treatment.

This study found that minoxidil provides cardioprotective effects in guinea-pig heart cells through selective activation of mitochondrial ATP-sensitive potassium channels.

This study found that Pomiferin demonstrated potent stimulation of extracellular matrix proteins in human dermal fibroblasts and hair follicles, suggesting its potential as an ingredient in skin and scalp treatments.

This study found that among women with female pattern hair loss, low-dose oral minoxidil improved hair loss severity and quality of life scores despite 71.6% experiencing mild to moderate unwanted hair growth, which most patients did not consider a reason to discontinue treatment.

This study investigated the effects of heat-treated Limosilactobacillus fermentum LM1020 on hair growth and reported increased hair density, improved cellular activity, and beneficial scalp microbiota changes in patients with androgenetic alopecia over 24 weeks.

This study evaluated high-dose oral minoxidil treatment in 57 patients with androgenetic alopecia and found it improved hair density by 10-30% in most cases, but 24.6% experienced adverse effects like hypertrichosis and tachycardia, indicating further research is needed to optimize safety and efficacy.

This literature review explores the mechanism of action, pharmacokinetics, safety, and efficacy of low-dose oral minoxidil as a treatment for various non-androgenic types of alopecia, finding it to be a promising alternative for these conditions despite the need to establish optimal dosing for different demographics.

Minoxidil helps hair growth by improving blood vessel function.

This study found that compound 4 from Urtica triangularis subsp. pinnatifida exhibited stronger anti-BPH activity against BPH-1 cells with an IC50 of 79.75 μM compared to finasteride's IC50 of 91.8 μM, while compounds 1, 2, and 5 showed moderate activity.

In castrated rats, this study found that triterpenoids from Ganoderma lucidum inhibited both types of 5α-reductase and reduced prostate growth linked to testosterone but not dihydrotestosterone.

Minoxidil improves blood flow in heart failure patients.

This study observed that liposomes encapsulating minoxidil and PEP penetrate the skin at a slower rate but may reach deeper layers compared to a foam formulation.

This study identified ten compounds from Eclipta prostrata, with some displaying potent inhibitory effects against α-glucosidase and acetylcholinesterase enzymes.

This prospective study observed that low-dose oral minoxidil improved anterior hairline and eyebrow coverage in adult women with frontal fibrosing alopecia and was generally well-tolerated.

In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.

In this study, researchers tested lotions containing DGLA, S-equol, and propionyl-l-carnitine on individuals with androgenic alopecia, noting a significant increase in hair count for women and a marginal increase for men after 6 months, along with improved hair cycle dynamics.

This review reports that myricetin, a naturally occurring antioxidant in plants, may assist in cancer management by enhancing the effects of existing drugs and inhibiting inflammatory markers, based on in vivo and in vitro studies.

This study found that a microneedle patch using manganese thiophosphite showed greater hair regrowth potential compared to minoxidil, even with less frequent application, for treating androgenetic alopecia.

The lotion helps manage mild to moderate hair loss.

This study found that compound 2 from Polygonum multiflorum increased dermal papilla cell proliferation and vibrissa follicle hair-fiber length more effectively than minoxidil in vitro, suggesting potential for alopecia treatment.

This study identified two potent 5α-reductase inhibitors from Tectona grandis leaves, and suggests that ethanol is a preferable solvent for extracting these compounds, which are potential ingredients for hair loss treatments.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

This study observed that while both minoxidil and botanically-derived 5-alpha reductase inhibitors significantly increased hair count and diameter in women with female pattern hair loss, minoxidil was more effective, especially for greater hair diameter increases, but had more troublesome side effects.

This study observed that administering low-dose oral minoxidil during the daytime led to significantly greater hair density improvements in androgenetic alopecia patients compared to nighttime dosing. This suggests that circadian variations in hair follicle biology could be important for optimizing treatment outcomes.

This review highlights that while low-dose oral minoxidil appears well-tolerated in cancer patients post-chemotherapy, its use during active chemotherapy has shown potential benefits but remains under investigation, with preclinical studies suggesting a protective effect against chemotherapy-induced alopecia.

This study found that minoxidil increased plasma renin activity in patients with hypertension through both an adrenergic mechanism related to heart rate changes and a secondary mechanism unrelated to propranolol.

This study found that dracorhodin perchlorate improved wound healing in diabetic rats by regulating the TLR4 pathway and related inflammatory factors.

This study found that Plumbago zeylanica extract and its component plumbagin may help prevent androgenetic alopecia by promoting dermal papilla cell growth and reducing SRD5A2 expression.